|Bid||1.1700 x 1800|
|Ask||1.1800 x 2200|
|Day's Range||1.1600 - 1.2489|
|52 Week Range||0.2000 - 4.3000|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
New patent covers ICOS T cell co-stimulation in combination with Heat's proprietary gp96 platformDURHAM, NC / ACCESSWIRE / October 7, 2020 / Heat Biologics, Inc.
DURHAM, NC / ACCESSWIRE / September 9, 2020 / Heat Biologics, Inc.
Superior pre-clinical activity compared to conventional costimulatory antibody combination administered systemicallyDURHAM, NC / ACCESSWIRE / September 2, 2020 / Heat Biologics, Inc.